Intrinsic Edge Capital Management LLC Sells 11,946 Shares of Vericel Co. (NASDAQ:VCEL)

Intrinsic Edge Capital Management LLC trimmed its position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 10.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,398 shares of the biotechnology company's stock after selling 11,946 shares during the quarter. Intrinsic Edge Capital Management LLC owned 0.20% of Vericel worth $5,348,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VCEL. Meeder Asset Management Inc. lifted its position in shares of Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock worth $129,000 after buying an additional 183 shares during the last quarter. Atria Investments Inc raised its position in Vericel by 2.4% during the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company's stock worth $437,000 after buying an additional 184 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock worth $1,312,000 after purchasing an additional 200 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of Vericel by 1.7% during the 4th quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company's stock worth $758,000 after purchasing an additional 234 shares during the period. Finally, Summit Investment Advisors Inc. grew its stake in shares of Vericel by 8.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,137 shares of the biotechnology company's stock worth $282,000 after purchasing an additional 405 shares during the period.

Analyst Ratings Changes

A number of brokerages recently commented on VCEL. Canaccord Genuity Group increased their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Stephens restated an "overweight" rating and set a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. Truist Financial dropped their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a report on Friday, April 11th. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $60.86.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the company's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now directly owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the transaction, the insider now directly owns 1,206 shares in the company, valued at $74,759.94. The trade was a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,034 shares of company stock worth $2,482,291 over the last 90 days. 5.20% of the stock is currently owned by company insiders.

Vericel Stock Down 3.4 %

VCEL stock traded down $1.34 during trading on Wednesday, reaching $38.02. 374,032 shares of the company's stock were exchanged, compared to its average volume of 449,226. Vericel Co. has a 1-year low of $37.76 and a 1-year high of $63.00. The company's fifty day moving average price is $45.08 and its 200-day moving average price is $51.32. The firm has a market cap of $1.91 billion, a PE ratio of 633.77 and a beta of 1.61.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.